Natural brain peptides that act on cannabinoid receptors can both help and hurt memory in mice

Researchers administered peptides directly into the brains (intracerebroventricular infusion) of mice before testing them on novel object recognition and object location recognition tasks. They tested healthy young mice and mice that had received amyloid-beta injections 14 days earlier to model Alzheimer's-like memory impairment. Various antagonists were used to confirm the receptor mechanisms.

This research reveals that the endocannabinoid system contains its own set of peptide regulators with opposing effects on memory. The finding that CB1 activation impairs memory in healthy brains but restores it in diseased brains highlights how context determines whether cannabinoid signaling helps or hurts cognition.

The brain produces its own cannabinoid-targeting peptides that can modulate memory in both directions depending on the health state of the brain. This dual nature could explain some of the conflicting findings about cannabis and cognition and suggests that cannabinoid-based therapies might need to be tailored based on whether the brain is healthy or impaired.

Peptides were delivered directly into the brain, a method not applicable to human treatment. The Alzheimer's model used (amyloid-beta injection) is simplified compared to actual disease progression. Mice were tested on relatively short timescales, leaving long-term effects unknown.